Another monoclonal antibody (mAb), ornartuzumab, targeting the hepatocyte growth factor receptor/tyrosine-protein kinase Met (HGFR/c-MET) receptor’s extracellular domain was reported to prevent the cancer growth in orthotopic U87 GBM xenograft. The gene discussed is MET; the disease is glioblastoma.